| TT |
Report |
Net Revenue (Q2 2026) |
BEAT |
pred ~$6.35B vs. cons $6.21B |
MEDIUM |
| TT |
Report |
Adj. EPS (Q2 2026) |
BEAT |
pred ~$4.40 vs. cons $4.264 |
MEDIUM |
| TT |
Report |
Americas Organic Growth (Q2 2026) |
BEAT |
pred ~8-9% vs. cons ~5.4% |
MEDIUM |
| TT |
Guide |
Adj. EPS (FY 2026) |
BETTER |
guide midpoint ~$15.10-$15.30 vs. cons $14.914 |
MEDIUM |
| TT |
Guide |
Adj. EPS (Q3 2026) |
BETTER |
guide ~$4.70-$4.80 vs. cons $4.595 |
MEDIUM |
| TT |
Guide |
Organic Revenue Growth (FY 2026) |
BETTER |
guide ~8-9% vs. cons ~7.2% |
MEDIUM |
| TT |
Return |
Day-1 residual (stock − beta × S&P 500) |
+6.0% |
— |
MEDIUM |
| TT |
Return |
5-day cumulative residual |
+8.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — estimate revisions follow the FY raise; sell-side models push Q3/Q4 up, sustaining the move over 5 days |
MEDIUM |